Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2510924 · 1 trial · 1 indication
PFS is defined as the time from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For participants who are still alive at the time of analysis and without evidence of tumor progression, PFS will be censored at the date of the most recent objective progression-free observation. For participants who receive subsequent anticancer therapy (except PCI) prior to objective disease progression or death, PFS will be censored at the date of the last objective progression-free observation prior to the date of subsequent therapy.
| Arm | Type | Description |
|---|---|---|
| LY2510924 + Carboplatin + Etoposide | EXPERIMENTAL | LY2510924: 20 milligram (mg) administered once daily as a subcutaneous(SC) injection on days 1 to 7 of the 21 day cycle; repeat every 21 days for 6 cycles. Carboplatin: 5 milligram/millimeter/per minute (mg/mL/min) area under the curve (AUC) administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles. Etoposide: 100 milligram square meter (mg/m\^2) administered intravenously on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles. |
| Carboplatin + Etoposide | ACTIVE_COMPARATOR | Carboplatin: 5 mg/mL/min area under the curve administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles. Etoposide: 100 milligram square meter (mg/m\^2) administered on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles. |
| Name | Type | Description |
|---|---|---|
| LY2510924 | DRUG | Administered subcutaneous injection |
| Carboplatin | DRUG | Administered intravenously |
| Etoposide | DRUG | Administered intravenously |
Inclusion Criteria: * histologically or cytologically confirmed extensive-stage disease small cell lung carcinoma * measurable disease as defined by the New Response Evaluation Criteria in Solid Tumors (RECIST): Revised RECIST Guideline (version 1.1) * no prior systemic chemotherapy, immunotherapy,...
LY2510924 is an investigational small molecule being studied for the treatment of extensive stage small cell lung carcinoma, a type of lung cancer that has spread beyond one lung and to other parts of the chest or body.
LY2510924 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY.
LY2510924 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and effectiveness.
LY2510924 has been studied in one completed Phase 2 clinical trial with the identifier NCT01439568. This trial enrolled 90 participants with extensive stage small cell lung carcinoma and was conducted in the United States.
LY2510924 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information.